A total of 712 samples out of 1512 (47%) with gastric cancer, most of which were adenocarcinoma, had altered expression levels of at least one of the SNXs (8% of samples with altered expression of SNX21, 7% of samples with altered expression of SNX12/23(KIF16B)/26, 6% of samples with altered expression of SNX16/25, 5% of samples with altered expression of SNX13/27/29, and other SNXs left with alteration frequency less than 5%; Fig. 6A). Here, SNX16 is linked to adenocarcinoma.